Atlas Trials

IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma

Clinical trial NCT01189383 · COMPLETED

Trial details

NCT number
NCT01189383
Sponsor
Baylor Research Institute
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Malignant Melanoma Stage IIIMalignant Melanoma Stage IV
Start date
2011-01-01
Primary completion
2016-12-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.